Unsere aktuellen Studien

Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group

A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/HER2- early breast cancer

A phase II single-arm, open-label study of atezolizumab and derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements - ADVANCE

A phase 2a/b, open label, proof-of-concept (Phase 2a) and double-blind, randomized, placebo-controlled (Phase 2b), multicenter, Efficacy and Safety study of AG-946 in participants with anemia due to lower-risk myelodysplastic syndroms

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha-or Beta-Thalassemia (ENERGIZE-T)

Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)

International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

International, multicenter, open-label clinical trail for the treatment of acute Myeloid Leukemia in children and adolescents

International cooperative study for children and adolescents with standard risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine.

A Phase 1b/2 Study of JNJ-75276617 in Combination with Standard Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations